The European NDDS market is estimated to hit USD 46.78 billion in 2016 and is expected to grow at a CAGR of 8.15% during the forecast period 2016-2021
The European market for NDDS is the second largest in the world, accounting for close to 30 % of the global market share. The requirements for innovative drug delivery have led to the need for controlling the pharmacokinetics, pharmacodynamics, non-specific toxicity, immunogenicity, biorecognition, and efficacy of drugs, in turn leading to the birth of drug delivery systems.
Unprecedented developments in genomics and molecular biology today offer a plethora of new drug targets. The method by which a drug is delivered to these targets can have a significant impact on its efficacy. The industries have diverted their research focus from the conventional dosage forms to novel drug delivery technologies that have significantly improved market requirements. In the recent years, the pharmaceutical companies have been struggling to maintain a balance between the pressure to drop prices and the high innovation costs. It is always advantageous for companies to develop their own innovative delivery devices to maintain a lead in the market.
Europe’s NDDS market has been segmented by the mode of delivery and region. By the mode of delivery, the market has been segmented into oral, pulmonary, transdermal and injectable drug delivery systems. These are further segmented by their modes of administration. By region, the market has been segmented into the UK, Germany, France, Switzerland, Spain and the Rest of Europe.
Some of the key players in the market are:
What the Report Offers